SCHEMBL23588128

SCHEMBL23588128

C=C(Cc1nc(C2(c3ccc(OCCCC)cc3)CC2)no1)C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ HTT P42858 1/20 0.35
▸ LMNA P02545 3/20 0.34
▸ TSHR P16473 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ PDE4A P27815 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ HDAC10 Q969S8 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ SMPD1 P17405 1/20 0.33
▸ MAPT P10636 2/20 0.33
▸ SPHK1 Q9NYA1 3/20 0.32
▸ PTGS2 P35354 1/20 0.32
▸ ADAMTS4 O75173 1/20 0.32
▸ MMP1 P03956 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23578242 0.89 KMT2A (0.36) MEN1KMT2AHTTLMNATSHR
SCHEMBL23578079 0.88 MEN1 (0.44) MEN1KMT2AHTTLMNATSHR
SCHEMBL25801800 0.86 KMT2A (0.46) MEN1KMT2AHTTLMNAALDH1A1
SCHEMBL29973341 0.86 S1PR1 (0.36) MEN1KMT2AHTTLMNAMAPT
SCHEMBL23578490 0.85 KMT2A (0.37) MEN1KMT2AHTTLMNATSHR
SCHEMBL25806244 0.85 KMT2A (0.37) MEN1KMT2AHTTLMNAALDH1A1
SCHEMBL23578419 0.85 KMT2A (0.37) MEN1KMT2AHTTLMNACYP2D6
SCHEMBL23578284 0.85 KMT2A (0.37) MEN1KMT2AHTTLMNAALDH1A1
SCHEMBL23588153 0.85 MEN1 (0.37) MEN1KMT2AHTTLMNATSHR
SCHEMBL23588198 0.85 CRHBP (0.35) MEN1KMT2AHTTLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 — — US disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 — — US disclosed
EP-4081511-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2022-11-02 — — EP disclosed
CN-115066418-A Carboxy derivatives with anti-inflammatory properties 西特瑞治疗有限公司 2022-09-16 — — CN disclosed
WO-2021130492-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 MEN1 4504/4885KMT2A 3125/4885HTT 4546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback